CSN Login
Members Online: 11

Research item on how variations in KRAS-wild status impact Cetuximab effectiveness

coloCan
Posts: 1849
Joined: Oct 2009

www.biomedcentral.com/1471-2407/13/169/abstract

(there's more info in the link attached but this is all rather "technical")

steved
Posts: 836
Joined: Apr 2004

Increasing thespecificity of chemo would be great. Preventing people who won't benefit from a drug having to be exposed to it will reduce the harm associated with them. 

Steve

coloCan
Posts: 1849
Joined: Oct 2009

here

www.onclive.com/publications/obtn/2013/march-2013/molecular-pathways-pathways-and-more-pathways/1 

Tho EGFR and KRAS get the most attention. (Hope with each passing day you feel better)

 

steved
Posts: 836
Joined: Apr 2004

Meeting with oncologist next week and will ask if testing anything more than kras in practice yet.

Slowly recovery moving forward here, thanks for your continued academic stimulation,

Steve

coloCan
Posts: 1849
Joined: Oct 2009

http://cancerres.aacrjournals.org/content/73/7/2059

Seems like every research team has their "pet" biomarker or factor that may predict future,so to speak. All here are aware of CEA but there may be other indicators as well that may be more pertinent

Subscribe with RSS
About Cancer Society

The content on this site is for informational purposes only. It is not a substitute for professional medical advice. Do not use this information to diagnose or treat a health problem or disease without consulting with a qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition. Use of this online service is subject to the disclaimer and the terms and conditions.

Copyright 2000-2014 © Cancer Survivors Network